The FDA approved the first treatment for patients with congenital thrombotic thrombocytopenic purpura (cTTP), which is a rare and life-threatening blood clotting disorder that may be fatal if left...
Researchers conducted a systematic review to assess the effect of CPAP treatment for obstructive sleep apnea on secondary cardiovascular disease events.
Researchers evaluated the association between two surgical excision approaches and overall survival for patients with pathologically confirmed, localized, early-stage Merkel cell carcinoma.
Researchers set out to compare the time until the next treatment in patients with chronic lymphocytic leukemia who are treated with single-agent ibrutinib at a sustained dose of 420 mg/day vs patients who...
Individuals with HIV are at higher risk of severe disease from COVID-19. In a recent study, researchers aimed to examine the factors that influence COVID-19 vaccine uptake in this patient population.
The once-monthly RNA interference injection medication received FDA approval based on results from the phase II PHYOX2 clinical trial and phase III PHYOX3 extension study.
A recent phase 3 trial showed that for untreated patients with chronic lymphocytic leukemia, measurable residual disease-directed ibrutinib–venetoclax therapy had superior progression-free survival compared...
Researchers evaluated whether patients with atherosclerotic cardiovascular disease (ASCVD) are utilizing high-intensity statins in their routine care of the disease.
The FDA approved pirtobrutinib for adults with either chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy.
